Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

Cameron, D. et al. (2002) Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? British Journal of Cancer, 87(12), pp. 1365-1369. (doi: 10.1038/sj.bjc.6600660)

Abstract

After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high risk, multiple node-positive breast cancer. For this reason it was identified as the standard arm for the Anglo-Celtic adjuvant high-dose chemotherapy trial. This study reports on the experience of this regimen in 329 women with early breast cancer involving at least four axillary nodes, who were treated outside any adjuvant chemotherapy trial. At a median follow-up of 3 years, the overall 5-year disease-free survival is 61%, and the overall survival is 70%. These data confirm the efficacy of this regimen in non-trial patients, and, for the same high risk subgroup, indicate that this approach offers an outcome at least as good as that seen in the CALGB 9344 AC-Taxol arm, and the NCIC days 1 and 8 CEF.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Evans, Professor Jeff
• Authors: Cameron, D., Anderson, A., Toy, E., Evans, T., Le Vay, J., Kennedy, I., Grieve, R., Perren, T., Jones, A., Mansi, J., Crown, J., and Leonard, R.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: British Journal of Cancer
• ISSN: 0007-0920